Could a One-Time keyhole surgery replace daily blood thinners for some heart patients?

NCT ID NCT07705282

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial compares a minimally invasive surgery that closes off a small heart pouch (the left atrial appendage) to standard blood-thinning medication in people with atrial fibrillation who have a high risk of bleeding. The goal is to see if the surgery can prevent strokes, major bleeds, and other heart-related events as well as or better than daily pills. Participants are either already on blood thinners or cannot take them due to medical reasons.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
video-assisted thoracoscopic closure of the left atrial appendage using a closure device
What this could lead to
If successful, this procedure could offer a safe alternative to long-term blood thinners for people with atrial fibrillation who are at high risk of bleeding.
What could go wrong
This is a large trial, but surgery carries risks like infection or complications from anesthesia. The procedure may not prove as effective as blood thinners in preventing strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 936 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2028

An estimate. Start dates often move.

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years and any of criteria 2-3 2. AF with a CHA2DS2-VA score ≥2 and a HAS-BLED score ≥3 or other clinically significant bleeding condition and ongoing OAC treatment 3. AF with a CHA2DS2-VA score ≥2 but deemed unfit for OAC by responsible physician due to clinical contraindications (e.g. amyloid angiopathy, previous intracranial haemorrhage or severe gastrointestinal bleeding). Exclusion Criteria: 1. Clinical frailty score ≥5 2. Indication for OAC other than AF 3. Indication for dual antiplatelet therapy, if OAC is discontinued 4. Previous open-heart surgery 5. Present indication for cardiac surgery 6. Present indication for ablation for atrial fibrillation 7. Previous radiation therapy of the chest, due to malignancy 8. Previous pericarditis or myocarditis 9. Previous surgery including access to the left pleural space 10. Documented FEV1\<70% or other significant pulmonary disease (including but not restricted to fibrosis, pulmonary post-covid syndrome, cystic fibrosis) 11. Ongoing treatment with corticosteroids or previous treatment for more than 3 consecutive months. 12. Allergy to contrast media 13. Patient already included in another interventional clinical trial 14. Patient listed abroad, which would render them to be lost to follow-up after discharge 15. Patient does not understand study information given in the local language or, for other reasons, is deemed unfit to participate according to the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial appendage closure for atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Skånes universitetssjukhus

    Lund, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.